Biotech Co. Zymergen Hits Ch. 11 In Del. Eyeing Asset Sale
Biotechnology company Zymergen Inc. on Tuesday filed for Chapter 11 protection in Delaware with both assets and debts of $100 million to $500 million, saying it's seeking an asset sale and...To view the full article, register now.
Already a subscriber? Click here to view full article